ANGO vs RCEL: stock comparison and AI forecast
Angiodynamics Inc (ANGO) and Avita Medical, Inc. (RCEL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ANGO Angiodynamics Inc
- Market Cap
- $493M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RCEL Avita Medical, Inc.
- Price
- $15.41 +260.0% · 6M
- Market Cap
- $474M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ANGO and RCEL have similar market capitalizations ($493M and $474M).
- ANGO turns -11.4% of its revenue into net income, against -57.0% for RCEL.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ANGO | RCEL |
|---|---|---|
| Market Cap | $493M | $474M |
| P/B Ratio | 3.01x | – |
| EPS | $-0.79 | $-1.61 |
| Book Value/Share | $3.90 | – |
| Revenue/Share | $7.74 | $2.45 |
| FCF/Share | $0.03 | $-0.80 |
Profitability & Margins
| Metric | ANGO | RCEL |
|---|---|---|
| ROE | -23.2% | – |
| ROA | -15.7% | -90.2% |
| ROIC | -20.1% | 168.2% |
| Gross Margin | 55.6% | 81.6% |
| Operating Margin | -11.0% | -46.6% |
| Net Margin | -11.4% | -57.0% |
| EBT Margin | -9.8% | -56.9% |
| Tax Rate | -0.5% | -0.1% |
Financial Health
| Metric | ANGO | RCEL |
|---|---|---|
| Current Ratio | 2.40x | 0.41x |
| Quick Ratio | 1.48x | 0.34x |
| D/E Ratio | 0.48x | – |
| Financial Leverage | 1.48x | – |
| Interest Coverage | 25.5x | -4.7x |
| Working Capital | $83M | -$40M |
Cash Flow
| Metric | ANGO | RCEL |
|---|---|---|
| Operating Cash Flow | $4M | -$24M |
| Free Cash Flow | $1M | -$25M |
| Capital Spending | -$2M | -$390K |
| FCF/Sales | 0.4% | -32.5% |
| CapEx/Sales | 0.7% | 0.5% |
Operational Efficiency
| Metric | ANGO | RCEL |
|---|---|---|
| Asset Turnover | 1.34x | 1.58x |
| Receivables Turnover | 7.2x | 7.7x |
| Inventory Turnover | 2.6x | 2.6x |
| Fixed Assets Turnover | 11.7x | 9.8x |
| Days Sales Outstanding | 50 days | 48 days |
| Days Inventory | 139 days | 138 days |
| Payables Period | 67 days | – |
| Cash Conversion Cycle | 122 days | – |
Income Statement
| Metric | ANGO | RCEL |
|---|---|---|
| Total Revenue | $325M | $76M |
| Operating Income | -$37M | -$35M |
| Net Income | -$38M | -$43M |
| R&D Expense | $31M | $20M |
| SG&A Expense | $187M | $90M |
| Cost of Goods Sold | $144M | $14M |
Dividend & Shareholder Information
| Metric | ANGO | RCEL |
|---|---|---|
| Shares Outstanding | 42M | 31M |
ANGO vs RCEL: stock comparison and AI forecast
Which is bigger, ANGO or RCEL?
ANGO and RCEL have similar market capitalizations ($493M and $474M).
Which one does Intratio's AI model rank higher, ANGO or RCEL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.